{{Rsnum
|rsid=1861494
|Gene=IFNG
|Chromosome=12
|position=68157629
|Orientation=plus
|GMAF=0.2746
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=IFNG
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.5 | 52.4 | 38.1
| HCB | 13.3 | 40.0 | 46.7
| JPT | 34.1 | 29.5 | 36.4
| YRI | 0.0 | 19.4 | 80.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 40.0 | 46.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20714752
|Title=IFNG +874 T&gt;A single nucleotide polymorphism is associated with leprosy among Brazilians
}}

{{PMID|15570643}} Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis.

{{PMID|16449530|OA=1
}} Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma.

{{PMID|17215375|OA=1
}} A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.

{{PMID|17327408|OA=1
}} Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.

{{PMID|18385742}} A single nucleotide polymorphism (A --> G) in intron 3 of IFNgamma gene is associated with asthma.

{{PMID|18633131|OA=1
}} Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

{{PMID|19066394|OA=1
}} Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma.

{{PMID|19126646|OA=1
}} Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA.

{{PMID|19356949|OA=1
}} Cytokine SNPs: Comparison of allele frequencies by race and implications for future studies.

{{PMID|20959405}} The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}